Three of the world’s largest pharmaceutical firms are dashing to develop a drug that mimics the effects of an exceedingly rare genetic mutation that causes LDL cholesterol levels to be dramatically low, writes Gina Kolata, of the New York Times.
Registering provides access to this and other free content.
Already have an account?Login Now.
A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.
National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.
In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.
The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.